Catalysts
Catalysts — What Can Move the Stock
The next six months are dominated by a single binary: the April 28, 2026 Q1 2026 earnings print — tomorrow, pre-market — where consensus sits at $1.85–$2.13 of adjusted EPS on roughly $47.5B of revenue and where the segment-level Health Benefits Ratio (HBR) is the only number that matters. The full-year $3+ EPS guide that anchors today's $42 print needs Q1 Medicaid HBR at or below the FY2025 exit of 93.7% and Marketplace HBR down 200+ bps from the 2025 segment exit; either bar in or out of reach resets the entire valuation debate. Beyond that single release, the calendar is materially thinner — a contested Senate vote on enhanced ACA premium tax credits, the May 12 annual meeting, and the June Wakely Marketplace risk-adjustment refresh are the only other soft windows that can independently move the stock inside six months.
Hard-dated events (next 6 mo)
High-impact catalysts
Next hard date (days away)
Signal Quality (1-5)
Q1 2026 earnings drop tomorrow (April 28, 2026, ~6:00 a.m. ET; call 8:30 a.m. ET). Zacks consensus $1.85 / Street $1.88–$2.13. The market has already paid for the $3+ FY26 guide — Q1 either confirms the recovery is structural or it is the trigger for re-rate to the $32 analyst low. Every other 2026 catalyst is downstream of how this one prints.
Ranked Catalyst Timeline
The table below ranks events by decision value to a PM, not by chronology. The Q1 print sits at the top because it resolves more of the debate, faster, than any other single event on the calendar.
The calendar is front-loaded and binary. After Q1 earnings tomorrow, the next genuinely material event for the stock is the EAPTC Senate vote window plus the June Wakely refresh, then Q2 earnings. The annual meeting is a governance event, not an earnings event. There is no investor day, no major M&A trigger, and no major regulatory decision dated inside the next 90 days other than CMS's already-finalized 2027 MA rate (April 6, 2026, 2.48% — already in the price).
Impact Matrix — what actually resolves the debate
Of the ten ranked items, four genuinely move underwriting. The remainder are either confirming context or governance noise.
Binder Error: Set operations can only apply to expressions with the same number of result columns
Three of the six matrix items resolve the bull thesis (cash engine durability, repricing efficacy, capital-return compounding); two resolve the bear thesis (Marketplace pool size, structural margin compression); one is genuinely variant (EAPTC outcome could re-rate the entire 2027+ earnings line). Q1 earnings sits in "both" because it can independently break either case.
Next 90 Days
The 90-day window is dominated by Q1 earnings. Everything else is either downstream of it or confirming context.
Technical context for the 90-day window: RSI is at 69.3 (within a hair of overbought) after a 1-month +28% move; the 50-day average volume has rolled back to 5.95M shares from the 19M post-shock peak — i.e., the rally into Q1 has been on lighter-than-average volume. The chart is set up for a binary move tomorrow rather than a slow grind: a beat resolves the resistance zone; a miss likely re-tests the $36 200-day moving average and, on a break, the $25 panic low.
What Would Change the View
Three observable signals would force the debate to update inside six months. First, a clean Q1 2026 segment HBR print — Medicaid at or below 93.7% and Marketplace down 200+ bps from the Q4 2025 exit — would validate the "mechanical recovery" leg of the bull thesis and shift the multiple debate from "is $3 EPS real" to "what's normalized." Second, the EAPTC Senate outcome plus the June Wakely Marketplace data are the single most important variant signal: a multi-year extension plus benign Wakely data removes the bear's 2027-2028 cliff and reopens the 5-year median 19x P/E; failure plus an adverse pool refresh would resurrect the exact mechanic that produced the $2.4B Q2 2025 hit. Third, the disposition of the new $4B Part D receivable purchase facility — flagged by the forensic work as a quality-of-earnings risk — will tell investors whether FY26 cash flow is genuinely $4B+ or facility-supported; this is the cleanest test of the "cash engine still works" leg of the bull thesis, and it shows up in plain sight in the 10-Q cash-flow footnote. Outside these three, the calendar is thin enough that the stock is more likely to drift on tape and ratings revisions than to move on news.